What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3, Pre-Registered Trial).

What question did this study set out to answer?

To compare the long-term effects of decitabine and standard chemotherapy on elderly AML patients leading to allografting.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows similar overall survival in elderly AML patients treated with decitabine and 3+7, indicating benefits in quality of life.

To compare the long-term effects of decitabine and standard chemotherapy on elderly AML patients leading to allografting.
Open-label, randomized, controlled phase III trial at 54 hospitals across 9 European countries
Patients aged ≥60 with newly diagnosed AML randomized to receive decitabine or 3+7 chemotherapy
Primary endpoint was overall survival; secondary endpoints included progression-free survival and health-related quality of life
23.7% in the decitabine group and 25.5% in the 3+7 group were alive at 6 years
Non-hematologic adverse events were lower in the decitabine group
Quality of life was better preserved in patients receiving decitabine compared to 3+7

Lübbert et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows similar overall survival in elderly AML patients treated with decitabine and 3+7, indicating benefits in quality of life.